Business
Abvance Therapeutics Secures Strategic Seed Financing & Leadership Expansion at ADA Scientific Sessions
CHICAGO, June 24, 2025 (GLOBE NEWSWIRE) -- Abvance Therapeutics, a biotechnology company developing next-generation glucagon analogs and therapies to prevent hypoglycemia and improve glucose management, today announced the closing of its initial seed financing led by Zubi Capital, in conjunction with the 85th Scientific Sessions of the American Diabetes Association, held in Chicago. The financing will support the company’s early development programs and expansion of its executive and board leade
About this update from Beta Bionics, Inc.
[{"type":"image","alt":"Abvance Therapeutics","displaySize":"","headline":null,"caption":"Abvance Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":231,"url":"https://media.zenfs.com/en/globenewswire.com/ccb5bc247c29ea69207d3ce38a711131"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ocd6yIE_WmaMftaiytpuaA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMyMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ccb5bc247c29ea69207d3ce38a711131","width":300,"height":231}},"lazy":false},{"type":"text","content":"CHICAGO, June 24, 2025 (GLOBE NEWSWIRE) -- Abvance Therapeutics, a biotechnology company developing next-generation glucagon analogs and therapies to prevent hypoglycemia and improve glucose management, today announced the closing of its initial seed financing led by Zubi Capital, in conjunction with the 85th Scientific Sessions of the American Diabetes Association, held in Chicago. The financing will support the company’s early development programs and expansion of its executive and board leadership.","length":506,"tagName":"p"},{"type":"text","content":"Abvance’s discovery platform builds on foundational research conducted at Vanderbilt University, including the work of Dr. Alan Cherrington, whose contributions helped shape the company’s scientific approach. Abvance is developing practical, predictable glucagon analogs—and co-formulations that include glucagon analogs—designed to integrate seamlessly into modern treatment regimens for people with diabetes.","length":410,"tagName":"p"},{"type":"text","content":"Edward Raskin has been appointed Chief Executive Officer, bringing extensive experience in diabetes-focused biotechnology and health technology. Mr. Raskin was previously a co-founder of Beta Bionics and played a key role in advancing the first bihormonal bionic pancreas. Dr. David Maggs, MD, a co-founder of Abvance, will serve as Chief Medical Officer. Rounding out the leadership team are Veena Rao, Ph.D. as Chief Operating and Commercial Officer, Michael Nguyen as Chief Development Officer, and Gibb Clarke as Chief Financial Officer.","length":541,"tagName":"p"},{"type":"text","content":"The company also announced the appointment of two new members to its Board of Directors: Jaivir Pall, Investment Director for diabetes at Zubi Capital, and Brent Ahrens, General Partner at Canaan Partners.","lengt...